No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LEGN240517C45000
- 0.73
- +0.38+108.57%
15min DelayClose May 14 16:00 ET
0.73High0.15Low
0.35Open0.35Pre Close145 Volume256 Open Interest45.00Strike Price2.80KTurnover51.82%IV2.69%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.73Time Value100Contract SizeAmericanOptions Type0.3970Delta0.1840Gamma77.18Leverage Ratio-0.1476Theta0.0014Rho30.64Eff Leverage0.0156Vega
Intraday
- 5D
- 1D
News
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Green Thumb Industries (OtherGTBIF) and OmniAb (OABI)
Legend Biotech's Loss Narrows in Q1 as Revenue Surges
Genscript Biotech's (HKG:1548) Nasdaq-listed subsidiary Legend Biotech reported a loss of $59.8 million, or $0.16 per share, in the first quarter, down from $112.1 million, or $0.34 per share, a year
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating for Legend Biotech Anchored by Carvykti's Growth and Market Penetration Potential
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Legend Biotech Is Maintained at Buy by HC Wainwright & Co.
Comments
🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
11
2
$Legend Biotech(LEGN.US$
waiting patiently for fda 😌🙏✨
waiting patiently for fda 😌🙏✨
2
🗓️ Last week’s PDUFAs:
$Akebia Therapeutics(AKBA.US$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US$ : 🤔
⇒...
$Akebia Therapeutics(AKBA.US$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US$ : 🤔
⇒...
8
4
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Vanda Pharmaceuticals(VNDA.US$ $Legend Biotech(LEGN.US$ $Supernus Pharmaceuticals(SUPN.US$ $ImmunityBio(IBRX.US$ $Aquestive Therapeutics(AQST.US$ $X4 Pharmaceuticals(XFOR.US$ $Liquidia(LQDA.US$ $Neurocrine Biosciences(NBIX.US$ $Moderna(MRNA.US$ $Day One Biopharmaceuticals(DAWN.US$
...
$Vanda Pharmaceuticals(VNDA.US$ $Legend Biotech(LEGN.US$ $Supernus Pharmaceuticals(SUPN.US$ $ImmunityBio(IBRX.US$ $Aquestive Therapeutics(AQST.US$ $X4 Pharmaceuticals(XFOR.US$ $Liquidia(LQDA.US$ $Neurocrine Biosciences(NBIX.US$ $Moderna(MRNA.US$ $Day One Biopharmaceuticals(DAWN.US$
...
21
2
$Legend Biotech(LEGN.US$ $Johnson & Johnson(JNJ.US$
⇨ FDA’s briefing docs released today! 🔔
⚠️ Early deaths in cilta-cel arm raise FDA concern despite PFS benefit... 🤔
$LEGN trending up ~6% after doc release 📈
ℹ️ CARVYKTI (ciltacabtagene autoleucel)
⇒ multiple myeloma
⇒ CARTITUDE-4 study
⇒ sBLA
⇒ PDUFA: 4/5/24
❓AdCom Discussion & Question:
Discussion Topic:
⇒ Discuss whether the results of CARTITUDE-4 provided in the supplemental application are sufficient to support a positive...
⇨ FDA’s briefing docs released today! 🔔
⚠️ Early deaths in cilta-cel arm raise FDA concern despite PFS benefit... 🤔
$LEGN trending up ~6% after doc release 📈
ℹ️ CARVYKTI (ciltacabtagene autoleucel)
⇒ multiple myeloma
⇒ CARTITUDE-4 study
⇒ sBLA
⇒ PDUFA: 4/5/24
❓AdCom Discussion & Question:
Discussion Topic:
⇒ Discuss whether the results of CARTITUDE-4 provided in the supplemental application are sufficient to support a positive...
3
Read more
Ginvest : Thank you for the timely info
Srav Reddy : $X4 Pharmaceuticals (XFOR.US)$ announcement was early on 29/4. But price receded. This is surprising to me.